Talphera Inc. (TLPH) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Talphera Inc. stock (TLPH) is currently trading at $0.80. Talphera Inc. PS ratio (Price-to-Sales) is 1215.35. Analyst consensus price target for TLPH is $3.25. WallStSmart rates TLPH as Sell.
- TLPH PE ratio analysis and historical PE chart
- TLPH PS ratio (Price-to-Sales) history and trend
- TLPH intrinsic value — DCF, Graham Number, EPV models
- TLPH stock price prediction 2025 2026 2027 2028 2029 2030
- TLPH fair value vs current price
- TLPH insider transactions and insider buying
- Is TLPH undervalued or overvalued?
- Talphera Inc. financial analysis — revenue, earnings, cash flow
- TLPH Piotroski F-Score and Altman Z-Score
- TLPH analyst price target and Smart Rating
Talphera Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Talphera Inc. (TLPH) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Talphera Inc. (TLPH) Key Strengths (0)
Supporting Valuation Data
Talphera Inc. (TLPH) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Very expensive at 1215.3x annual revenue
Micro-cap company with very limited liquidity and high volatility
Fairly priced relative to book value
Moderate institutional interest at 43.15%
Supporting Valuation Data
Talphera Inc. (TLPH) Detailed Analysis Report
Overall Assessment
This company scores 17/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 0 register as strengths (avg 0/10) while 6 fall into concern territory (avg 2.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (1215.35), Price/Book (2.02) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -86.50%, Operating Margin at -46525.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -86.50% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TLPH Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TLPH's Price-to-Sales ratio of 1215.35x sits near its historical average of 1392.3x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 20% below its historical high of 1517.48x set in Mar 2026, and 0% above its historical low of 1215.35x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~1517.5x as trailing revenue scaled faster than the stock price.
Compare TLPH with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Talphera Inc. (TLPH) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Talphera Inc. operates as a stable business with moderate growth and solid fundamentals. Revenue reached 28,000 with 0% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 5575% of revenue (2M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Talphera Inc..
Bottom Line
Talphera Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Talphera Inc.(TLPH)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Talphera Inc. is a pioneering biotechnology firm specializing in the development of advanced therapies targeting rare diseases and significant unmet medical needs. The company leverages its expertise in peptide-based therapeutics to address critical challenges in cancer treatment and other high-need health areas. With a robust pipeline of innovative therapeutic candidates and a strong dedication to research excellence, Talphera is well-positioned for transformative contributions to the healthcare sector. For institutional investors, Talphera represents a compelling opportunity to engage with a growth-oriented company in the expanding biotechnology landscape.